Ajai Chari, MD, discusses the rationale for using combination therapy in patients with multiple myeloma.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the rationale for using combination therapy in patients with multiple myeloma.
Historically, Chari says that every drug in the treatment landscape has only worked for a short period of time in these patients. Because of this, the agents are combined to increase both response and duration of response, while also decreasing resistance.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More